Monday, June 22, 2026

SLUSH FUND SCAM: Korean Officials Used Communist Tactics To Steal Millions From Taxpayers

Uiseong County faces scrutiny for purchasing land without proper procedures, raising concerns of favoritism and misuse of taxpayer funds.

North Korea Intensifies Ideological Crackdown in Border City of Kaesong, Prosecutor Calls for Stronger Legal Campaign

North Korea intensifies ideological control in Kaesong, targeting luxury lifestyles and foreign influences as threats to socialism.

2026: Will North Korea’s Nuclear Freeze Open the Door to U.S. Talks?

Experts urge South Korea to prepare for phased denuclearization talks with North Korea and the U.S., balancing engagement and pressure.

Jin Joong Hwang

Author's Latest

Korean Medical AI Lands at the University of Washington: Neurofit Signs U.S. Deal for Brain MRI + PET Analysis Tools

Neurofit signs a contract to supply AI medical solutions to the University of Washington, marking its U.S. market entry and expansion.

Unlocking Weight Loss: Hanmi Pharmaceutical’s Innovative H.O.P Project and the Game-Changing Epaglenatide

Hanmi Pharmaceutical is innovating obesity treatment with efpeglenatide and HM15275, focusing on tailored solutions for Korean patients.

NCCN Endorses Leclaza and Rybrevant Combo as Top Lung Cancer Treatment: What You Need to Know

NCCN guidelines now classify Leclaza + Rybrevant as a preferred first-line treatment for lung cancer, enhancing patient access and management.

Celltrion Gets Global IB Upgrades: Morgan Stanley Raises Target to $206.25 as New Biosimilars Lift Margins

Celltrion is expanding through biosimilars and new drug development, attracting global investor interest and raising target stock prices.

How ABL Bio’s Grabody-B Revolutionizes siRNA Delivery: A Game-Changer for Brain Disease Treatment?

ABL Bio's Grabody-B technology effectively delivers siRNA across the blood-brain barrier, enhancing treatment for brain and systemic diseases.

SJN314: The Promising New Immunotherapy for Chronic Inflammatory Diseases in Asia

Samjin Pharmaceutical submits phase 1 trial plan for SJN314, targeting immune diseases, aiming for global partnerships in early clinical phases.

How Celltrion’s Omlyclo is Dominating Spain’s Omalizumab Market: A First-Mover Success Story

Celltrion's Omlyclo treatment is thriving in Spain, capturing over 60% of the omalizumab market with innovative strategies and strong demand.

GC Biopharma Corp Soars After Eight Years on the Back of Immunodeficiency Drug Alyglo, Posting Results in U.S. Market Push

GC Biopharma Corp breaks its fourth-quarter deficit with ALYGLO's success, achieving $106M in annual revenue and plans for future growth.

GCC2005: The Breakthrough CAR-NK Therapy for T-Cell Lymphoma Unveiled at TCLF 2026

GC Cell presents promising CD5-targeting CAR-NK therapy GCC2005 for T-cell lymphoma, showing significant efficacy and safety at TCLF.

How SK Chemical’s Nose-R Soft Cap Stand Out in Allergy Treatment: A Deep Dive into the OTC Market

SK Chemicals partners with Kyung Nam Pharm to enhance Nose-R Soft Cap sales in pharmacies, boosting allergy treatment distribution.

Celltrion’s Zymfentra: How This Breakthrough Drug is Driving Record Sales

Celltrion expects record sales driven by Zymfentra's success, expanding into new biosimilars and CDMO business for future growth.

Chinese Biotech’s Rise: What’s the Standard of Global Tech Trade?

Analysts at the JPMHC noted a shift in biotech, with firms resisting sales and China emerging as a tech transfer leader.

Revolutionary Cancer Treatment SJ-650: What Makes It a Game Changer in Oncology?

SillaJen's SJ-650 cancer treatment platform gains recognition with publication in Molecular Therapy, showcasing its innovative approach and efficacy.

Unlock Youthful Skin: A Comprehensive Guide to Elabie Premier Fillers Launched in Thailand

Humedics launches Elavie Premier HA fillers in Thailand, marking significant expansion in Southeast Asia with a successful symposium.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.